- Home
- HOWL vs ARMP Comparison
HOWL vs ARMP Comparison
Compare HOWL & ARMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | HOWL | ARMP |
|---|---|---|
| Founded | 2017 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 64.5M | 125.7M |
| IPO Year | 2021 | N/A |
Fundamental Metrics
Financial Performance| Metric | HOWL | ARMP |
|---|---|---|
| Price | $1.10 | $5.67 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 1 |
| Target Price | $7.00 | ★ $9.00 |
| AVG Volume (30 Days) | ★ 498.4K | 69.4K |
| Earning Date | 11-04-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $5,054,000.00 |
| Revenue This Year | N/A | $4.48 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.60 | $0.90 |
| 52 Week High | $2.38 | $16.34 |
Technical Indicators
Market Signals| Indicator | HOWL | ARMP |
|---|---|---|
| Relative Strength Index (RSI) | 52.22 | 49.10 |
| Support Level | $0.96 | $5.49 |
| Resistance Level | $1.03 | $6.18 |
| Average True Range (ATR) | 0.09 | 0.54 |
| MACD | 0.04 | -0.18 |
| Stochastic Oscillator | 96.55 | 31.51 |
Price Performance
Historical ComparisonAbout HOWL Werewolf Therapeutics Inc.
Werewolf Therapeutics Inc is a biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer. It is leveraging its proprietary PREDATOR platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. Its INDUKINE molecules are intended to remain inactive in peripheral tissue yet activate selectively in the tumor microenvironment or TME.
About ARMP Armata Pharmaceuticals Inc.
Armata Pharmaceuticals Inc is a developer of pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its proprietary bacteriophage-based technology. The company is developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, Staphylococcus aureus, and other pathogens. In addition, in collaboration with Merck, the company is developing proprietary synthetic phage candidates to target an undisclosed infectious disease agent.